Tetra Bio-Pharma Confirms Submission of Two OTC DIN Applications to Health Canada – Yahoo Finance

TBP.V) (TBPMF) today announced that it has submitted two over-the-counter (OTC) DIN applications to Health Canada. The first application, submitted on November 15^th, is for the treatment of hemorrhoids. The second application, submitted today, November 26^th, is for the temporary relief of aches and pains of muscles and joints associated with backache, lumbago, strains, bruises, sprains and arthritic or rheumatic pain, pain of tendons and ligaments. 

Tetra continues to expect commercial launch in Canada in pharmacy retail outlets in early 2020, and is in commercial agreement discussions with various companies for the sale and distribution of these products. Tetra also plans to launch these products in the United States market in 2020. In preparation for a U.S. launch, Tetra is in discussions with a contract manufacturer to set up the manufacturing and to obtain a National Drug Code (NDC) number from the U.S. Food and Drug Administration (FDA) for each drug, which is required for all OTC drugs sold in the U.S.

TBP.V) (TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

www.tetrabiopharma.com
Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Story continues